Compare CMC & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMC | CELC |
|---|---|---|
| Founded | 1915 | 2011 |
| Country | United States | United States |
| Employees | N/A | 155 |
| Industry | Steel/Iron Ore | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 7.0B |
| IPO Year | 1994 | 2017 |
| Metric | CMC | CELC |
|---|---|---|
| Price | $71.74 | $139.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | $73.33 | ★ $112.56 |
| AVG Volume (30 Days) | 773.7K | ★ 1.1M |
| Earning Date | 03-26-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.20% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.41 | N/A |
| Revenue | ★ $7,918,430,000.00 | N/A |
| Revenue This Year | $18.81 | N/A |
| Revenue Next Year | $6.34 | $720.19 |
| P/E Ratio | $29.34 | ★ N/A |
| Revenue Growth | ★ 25.57 | N/A |
| 52 Week Low | $45.50 | $10.26 |
| 52 Week High | $84.87 | $151.02 |
| Indicator | CMC | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 57.28 | 59.55 |
| Support Level | $67.91 | $100.58 |
| Resistance Level | $72.41 | $151.02 |
| Average True Range (ATR) | 1.98 | 8.59 |
| MACD | -0.07 | 0.61 |
| Stochastic Oscillator | 71.06 | 70.48 |
Commercial Metals Co is a manufacturer and supplier of early-stage construction materials, including steel reinforcing bars, concrete pipes, precast products, and soil stabilization solutions. It also produces merchant bar, steel fence posts, and wire rod, serving domestic and some international markets in Europe and Asia. Its products are used in infrastructure and building projects such as highways, bridges, airports, and commercial and residential buildings.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.